HER2 Expression in Urothelial Carcinoma, a Systematic Literature Review

Overview

Journal Front Oncol

Specialty Oncology

Date 2022 Nov 7

PMID 36338710

Authors

Emilie Scherrer

Ashley Kang

Lisa M Bloudek

Vadim S Koshkin

Affiliations

Soon will be listed here.

Abstract

Background: Urothelial carcinoma (UC) is a common malignancy with significant associated mortality. Recent clinical trials suggest an emerging role for HER2-targeted therapy. Testing for HER2 expression in UC is not part of current routine clinical practice. In consequence, the prevalence of HER2 expression in UC is not well defined.

Methods: A systematic literature review (SLR) was conducted to characterize HER2 expression in both locally advanced unresectable or metastatic (LA/mUC) and earlier stage UC, classified as HER2+, HER2-low, HER2-. HER2+ was defined as an immunohistochemistry (IHC) score of 3+ or IHC 2+ and ISH/FISH+. HER2-low was defined as an IHC score of 2+ and ISH/FISH- or IHC 1+. HER2- was defined as an IHC score of 0. Weighted averages were calculated to generate an estimate of the population prevalence.

Results: A total of 88 studies were identified, with 45, 30, and 13 studies investigating LA/mUC, earlier stage UC, and mixed stage/unspecified, respectively. The most common assays used were Dako HercepTest and Ventana Pathway anti-HER2/neu (4B5) for IHC to assess HER2 protein expression; Abbott PathVysion HER-2 DNA Probe Kit, FoundationOne CDx, and Guardant360 CDx for assessing HER2 gene amplification. The most frequently cited scoring guidelines were ASCO/CAP guidelines for breast cancer and gastric cancer, though most studies defined their own criteria for HER2 expression. Using the pre-specified definition, HER2+ prevalence ranged from 6.7% to 37.5% with a weighted average of 13.0% in LA/mUC. Only 1 study presented data that could be classified as HER2+ based on pre-specified criteria in earlier stage UC patients, and this study represented a likely outlier, at 76.0%.

Conclusion: The results from this SLR help to shed light on HER2 expression in UC, a potentially clinically relevant biomarker-driven subpopulation for emerging HER2-directed regimens. Results of this SLR illuminate the variability in how HER2+ status expression levels are being assessed and how HER2+ is defined. Consensus on standardized HER2 testing and scoring criteria is paramount to better understand the clinical relevance in patients with UC.

Citing Articles

Non-invasive assessment of HER2 expression in patients with urothelial carcinoma using [68Ga]Ga-HER2 affibody PET/CT imaging: preliminary clinical findings.

Zou S, Liu Z, Zhou J, Song S, Wang D, Zhu D Eur J Nucl Med Mol Imaging. 2025; .

PMID: 39951137 DOI: 10.1007/s00259-025-07142-0.

Prevalence and Clinical Outcomes of Human Epidermal Growth Factor Receptor 2 Expression in Patients With Advanced Urothelial Carcinoma.

Ortiz-Calderon I, Arias-Ruiz L, Dorantes-Heredia R, Ruiz-Morales J World J Oncol. 2025; 16(1):51-58.

PMID: 39850531 PMC: 11750760. DOI: 10.14740/wjon1966.

Clinical significance of HER2 in urothelial carcinoma and analysis of its correlation with glycolytic metabolic characteristics.

Guo A, Wu C, Cao J, Zhu K, Ding S Front Mol Biosci. 2025; 11:1521889.

PMID: 39822391 PMC: 11736410. DOI: 10.3389/fmolb.2024.1521889.

Targeted therapies and molecular targets in the therapeutic landscape of advanced urothelial carcinoma: state of the art and future perspectives.

Testi I, Giudice G, Salfi G, Pedrani M, Merler S, Turco F Explor Target Antitumor Ther. 2025; 5(6):1326-1364.

PMID: 39764422 PMC: 11702265. DOI: 10.37349/etat.2024.00279.

The Role of Antibody-Drug Conjugates in Urothelial Cancer: A Review of Recent Advances in the Treatment of Locally Advanced and Metastatic Urothelial Cancer.

Vlachou E, Johnson B, Hoffman-Censits J Clin Med Insights Oncol. 2024; 18:11795549241290787.

PMID: 39686979 PMC: 11648052. DOI: 10.1177/11795549241290787.

References

Perez E, Barrios C, Eiermann W, Toi M, Im Y, Conte P . Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE. Cancer. 2019; 125(22):3974-3984. DOI: 10.1002/cncr.32392. View

Vandekerkhove G, Lavoie J, Annala M, Murtha A, Sundahl N, Walz S . Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer. Nat Commun. 2021; 12(1):184. PMC: 7794518. DOI: 10.1038/s41467-020-20493-6. View

Bolenz C, Shariat S, Karakiewicz P, Ashfaq R, Ho R, Sagalowsky A . Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder. BJU Int. 2010; 106(8):1216-22. DOI: 10.1111/j.1464-410X.2009.09190.x. View

Abel M, Burkenroad A, Sun A, Lu E, Stefanoudakis D, Drakaki A . The Evolving Landscape of Antibody-Drug Conjugates for Urothelial Carcinoma. Clin Genitourin Cancer. 2021; 19(3):183-193. DOI: 10.1016/j.clgc.2020.11.006. View

Bang Y, Van Cutsem E, Feyereislova A, Chung H, Shen L, Sawaki A . Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376(9742):687-97. DOI: 10.1016/S0140-6736(10)61121-X. View

Wester K, Sjostrom A, de la Torre M, Carlsson J, Malmstrom P . HER-2--a possible target for therapy of metastatic urinary bladder carcinoma. Acta Oncol. 2002; 41(3):282-8. DOI: 10.1080/02841860260088836. View

Coogan C, Estrada C, Kapur S, Bloom K . HER-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder. Urology. 2004; 63(4):786-90. DOI: 10.1016/j.urology.2003.10.040. View

Ross J, Wang K, Al-Rohil R, Nazeer T, Sheehan C, Otto G . Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy. Mod Pathol. 2013; 27(2):271-80. DOI: 10.1038/modpathol.2013.135. View

Hansel D, Amin M, Comperat E, Cote R, Knuchel R, Montironi R . A contemporary update on pathology standards for bladder cancer: transurethral resection and radical cystectomy specimens. Eur Urol. 2012; 63(2):321-32. DOI: 10.1016/j.eururo.2012.10.008. View

10.

Oudard S, Culine S, Vano Y, Goldwasser F, Theodore C, Nguyen T . Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2. Eur J Cancer. 2014; 51(1):45-54. DOI: 10.1016/j.ejca.2014.10.009. View

11.

Zhao J, Xu W, Zhang Z, Song R, Zeng S, Sun Y . Prognostic role of HER2 expression in bladder cancer: a systematic review and meta-analysis. Int Urol Nephrol. 2014; 47(1):87-94. DOI: 10.1007/s11255-014-0866-z. View

12.

Vandekerkhove G, Todenhofer T, Annala M, Struss W, Wong A, Beja K . Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer. Clin Cancer Res. 2017; 23(21):6487-6497. DOI: 10.1158/1078-0432.CCR-17-1140. View

13.

Goodman A, Osunkoya A . Human epidermal growth factor receptor 2 expression in micropapillary urothelial carcinoma of the bladder: an analysis of 27 cases. Hum Pathol. 2016; 57:160-164. DOI: 10.1016/j.humpath.2016.07.014. View

14.

Naruse K, Yamada Y, Nakamura K, Aoki S, Taki T, Zennami K . Potential of molecular targeted therapy of HER-2 and Cox-2 for invasive transitional cell carcinoma of the urinary bladder. Oncol Rep. 2010; 23(6):1577-83. DOI: 10.3892/or_00000798. View

15.

Rosenberg J, Hoffman-Censits J, Powles T, van der Heijden M, Balar A, Necchi A . Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016; 387(10031):1909-20. PMC: 5480242. DOI: 10.1016/S0140-6736(16)00561-4. View

16.

Powles T, Duran I, van der Heijden M, Loriot Y, Vogelzang N, De Giorgi U . Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2017; 391(10122):748-757. DOI: 10.1016/S0140-6736(17)33297-X. View

17.

Patelli G, Zeppellini A, Spina F, Righetti E, Stabile S, Amatu A . The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: A systematic review and future perspectives. Cancer Treat Rev. 2022; 104:102351. DOI: 10.1016/j.ctrv.2022.102351. View

18.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7):e1000097. PMC: 2707599. DOI: 10.1371/journal.pmed.1000097. View

19.

Kruger S, Weitsch G, Buttner H, Matthiensen A, Bohmer T, Marquardt T . HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications. Int J Cancer. 2002; 102(5):514-8. DOI: 10.1002/ijc.10731. View

20.

Madison R, Gupta S, Elamin Y, Lin D, Pal S, Necchi A . Urothelial cancer harbours EGFR and HER2 amplifications and exon 20 insertions. BJU Int. 2020; 125(5):739-746. DOI: 10.1111/bju.15006. View